This antibody inhibits the growth and invasion of different tumor cell lines, and shows a potent anti-tumor effect in in vivo models of both HGF-dependent and HGF-independent MET activation, including a MET-amplified lung cancer xenopatient. Here, HGF is linked to lung carcinoma.